vs
Side-by-side financial comparison of Dexcom (DXCM) and TTM TECHNOLOGIES INC (TTMI). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $846.0M, roughly 1.5× TTM TECHNOLOGIES INC). Dexcom runs the higher net margin — 21.2% vs 5.9%, a 15.3% gap on every dollar of revenue. On growth, TTM TECHNOLOGIES INC posted the faster year-over-year revenue change (30.4% vs 21.6%). Over the past eight quarters, TTM TECHNOLOGIES INC's revenue compounded faster (21.8% CAGR vs 12.0%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
TTM Technologies, Inc. is an American printed circuit board (PCB) manufacturer headquartered in Santa Ana, California. Founded in 1998, the company is one of the top five PCB manufacturers in the world and the largest in North America, and the largest supplier of PCBs to the U.S. military. TTM serves customers in industries including aerospace and defense, medical, industrial, automotive, computing, and networking.
DXCM vs TTMI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $846.0M |
| Net Profit | $267.3M | $50.0M |
| Gross Margin | 62.9% | 21.4% |
| Operating Margin | 25.6% | 8.6% |
| Net Margin | 21.2% | 5.9% |
| Revenue YoY | 21.6% | 30.4% |
| Net Profit YoY | 153.6% | 55.3% |
| EPS (diluted) | $0.67 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $846.0M | ||
| Q4 25 | $1.3B | $774.3M | ||
| Q3 25 | $1.2B | $752.7M | ||
| Q2 25 | $1.2B | $730.6M | ||
| Q1 25 | $1.0B | $648.7M | ||
| Q4 24 | $1.1B | $651.0M | ||
| Q3 24 | $994.2M | $616.5M | ||
| Q2 24 | $1.0B | $570.1M |
| Q1 26 | $267.3M | $50.0M | ||
| Q4 25 | $267.3M | $50.7M | ||
| Q3 25 | $283.8M | $53.1M | ||
| Q2 25 | $179.8M | $41.5M | ||
| Q1 25 | $105.4M | $32.2M | ||
| Q4 24 | $151.7M | $5.2M | ||
| Q3 24 | $134.6M | $14.3M | ||
| Q2 24 | $143.5M | $10.5M |
| Q1 26 | 62.9% | 21.4% | ||
| Q4 25 | 62.9% | 21.4% | ||
| Q3 25 | 60.5% | 20.8% | ||
| Q2 25 | 59.5% | 20.3% | ||
| Q1 25 | 56.9% | 20.2% | ||
| Q4 24 | 58.9% | 19.4% | ||
| Q3 24 | 59.7% | 21.1% | ||
| Q2 24 | 62.4% | 18.2% |
| Q1 26 | 25.6% | 8.6% | ||
| Q4 25 | 25.6% | 10.4% | ||
| Q3 25 | 20.1% | 9.6% | ||
| Q2 25 | 18.4% | 8.5% | ||
| Q1 25 | 12.9% | 7.7% | ||
| Q4 24 | 17.0% | 1.4% | ||
| Q3 24 | 15.3% | 8.3% | ||
| Q2 24 | 15.7% | 3.0% |
| Q1 26 | 21.2% | 5.9% | ||
| Q4 25 | 21.2% | 6.5% | ||
| Q3 25 | 23.5% | 7.0% | ||
| Q2 25 | 15.5% | 5.7% | ||
| Q1 25 | 10.2% | 5.0% | ||
| Q4 24 | 13.6% | 0.8% | ||
| Q3 24 | 13.5% | 2.3% | ||
| Q2 24 | 14.3% | 1.8% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.47 | ||
| Q3 25 | $0.70 | $0.50 | ||
| Q2 25 | $0.45 | $0.40 | ||
| Q1 25 | $0.27 | $0.31 | ||
| Q4 24 | $0.37 | $0.05 | ||
| Q3 24 | $0.34 | $0.14 | ||
| Q2 24 | $0.35 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $410.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $1.8B |
| Total Assets | $6.3B | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | $410.0M | ||
| Q4 25 | $917.7M | $501.2M | ||
| Q3 25 | $1.8B | $491.1M | ||
| Q2 25 | $1.2B | $448.0M | ||
| Q1 25 | $904.9M | $411.3M | ||
| Q4 24 | $606.1M | $503.9M | ||
| Q3 24 | $621.2M | $469.5M | ||
| Q2 24 | $939.2M | $440.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $916.2M | ||
| Q3 25 | — | $916.6M | ||
| Q2 25 | — | $917.1M | ||
| Q1 25 | — | $917.6M | ||
| Q4 24 | — | $914.4M | ||
| Q3 24 | — | $912.8M | ||
| Q2 24 | — | $913.9M |
| Q1 26 | $2.7B | $1.8B | ||
| Q4 25 | $2.7B | $1.8B | ||
| Q3 25 | $2.7B | $1.7B | ||
| Q2 25 | $2.6B | $1.6B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.1B | $1.6B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.4B | $1.5B |
| Q1 26 | $6.3B | $4.0B | ||
| Q4 25 | $6.3B | $3.8B | ||
| Q3 25 | $7.5B | $3.7B | ||
| Q2 25 | $7.3B | $3.6B | ||
| Q1 25 | $6.8B | $3.5B | ||
| Q4 24 | $6.5B | $3.5B | ||
| Q3 24 | $6.4B | $3.4B | ||
| Q2 24 | $6.8B | $3.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.59× | ||
| Q2 24 | — | 0.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
TTMI
| Commercial | $495.0M | 59% |
| Aerospace & Defense | $351.7M | 42% |
| Medical, Industrial, and Instrumentation | $16.0K | 0% |
